A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung

Trial Profile

A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 26 Jun 2018 Primary endpoint has been met. (Objective Response Rate)
    • 05 Jun 2018 Results assessing identification of predictive and pharmacodynamic biomarkers from NCT02488408, NCT03184571, NCT03184558 NCT02872259, NCT02424617 and NCT02922777 trials presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=13; as of Feb 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top